Secretome Therapeutics, a biotech company developing a novel cell therapy approach for inflammatory diseases, has secured $30.0M in Series A funding. The round, led by RA Capital Management, provides substantial capital to advance its work in leveraging neonatal cardiac progenitor cells and their secretomes.
This investment underscores confidence in Secretome Therapeutics' mission to revolutionize how these conditions are treated. The fresh capital will support the company's ongoing efforts to bring its innovative therapies closer to patients.













